- Erratum to ‘KASL clinical practice guidelines for management of chronic hepatitis B’ [Clin Mol Hepatol 2022;28:276-331]
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2534361
- Clin Mol Hepatol.
- 2022 Oct;28(4):940-940.
- doi: 10.3350/cmh.2022.0084.e1
-
- CITED
-
- Close
- SHARE
-
- Close
- 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
-
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea
- KMID: 2534337
- Clin Mol Hepatol.
- 2022 Oct;28(4):583-705.
- doi: 10.3350/cmh.2022.0294
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is... -
- CITED
-
- Close
- SHARE
-
- Close
- Personalized medicine in nonalcoholic fatty liver disease
-
Pirola CJ, Sookoian S
- KMID: 2534359
- Clin Mol Hepatol.
- 2022 Oct;28(4):935-938.
- doi: 10.3350/cmh.2022.0175
-
- CITED
-
- Close
- SHARE
-
- Close
- Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
-
Pirola CJ, Sookoian S
- KMID: 2534345
- Clin Mol Hepatol.
- 2022 Oct;28(4):806-809.
- doi: 10.3350/cmh.2022.0208
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘History and future of hepatitis B virus control in South Korea’ [Clin Mol Hepatol 2021;27:620-622]
-
Kim DY
- KMID: 2534360
- Clin Mol Hepatol.
- 2022 Oct;28(4):939-939.
- doi: 10.3350/cmh.2021.0277.e1
-
- CITED
-
- Close
- SHARE
-
- Close
- Surveillance for hepatocellular carcinoma: It is time to move forward
-
Kim BH, Cho Y, Park JW
- KMID: 2534346
- Clin Mol Hepatol.
- 2022 Oct;28(4):810-813.
- doi: 10.3350/cmh.2022.0257
-
- CITED
-
- Close
- SHARE
-
- Close
- Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
-
Lee SK, Kwon JH, Yoon N, Nam SW, Sung PS
- KMID: 2534355
- Clin Mol Hepatol.
- 2022 Oct;28(4):926-928.
- doi: 10.3350/cmh.2022.0233
-
- CITED
-
- Close
- SHARE
-
- Close
- Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
-
Kim SS, Cheong JY
- KMID: 2534344
- Clin Mol Hepatol.
- 2022 Oct;28(4):802-805.
- doi: 10.3350/cmh.2022.0249
-
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
-
Jeong S, Kim W, Park SM
- KMID: 2534358
- Clin Mol Hepatol.
- 2022 Oct;28(4):933-934.
- doi: 10.3350/cmh.2022.0267
-
- CITED
-
- Close
- SHARE
-
- Close
- Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology
-
Lee SH, Jang HJ
- KMID: 2534341
- Clin Mol Hepatol.
- 2022 Oct;28(4):754-772.
- doi: 10.3350/cmh.2021.0394
Molecular tests are necessary to stratify cancer patients for targeted therapy. However, high cost and technical barriers limit the application of these tests, hindering optimal treatment. Recently, deep learning (DL)... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies
-
Lu LY, Wu MY, Kao YS, Hung CH
- KMID: 2534357
- Clin Mol Hepatol.
- 2022 Oct;28(4):931-932.
- doi: 10.3350/cmh.2022.0259
-
- CITED
-
- Close
- SHARE
-
- Close
- Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
-
Ng CH, Huang DQ, Nguyen MH
- KMID: 2534343
- Clin Mol Hepatol.
- 2022 Oct;28(4):790-801.
- doi: 10.3350/cmh.2022.0070
Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world’s adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Forms of cholangitis to be considered after SARS-CoV-2 infection
-
Cho JY, Lee YS, Kim SS, Song DS, Lee JH, Kim JH
- KMID: 2534356
- Clin Mol Hepatol.
- 2022 Oct;28(4):929-930.
- doi: 10.3350/cmh.2022.0260
-
- CITED
-
- Close
- SHARE
-
- Close
- Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
-
Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH
- KMID: 2534349
- Clin Mol Hepatol.
- 2022 Oct;28(4):841-850.
- doi: 10.3350/cmh.2022.0239
Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD.... -
- CITED
-
- Close
- SHARE
-
- Close
- Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
-
Miao L, Xu J, Targher G, Byrne CD, Zheng MH
- KMID: 2534339
- Clin Mol Hepatol.
- 2022 Oct;28(4):725-738.
- doi: 10.3350/cmh.2022.0015
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review
-
Kim SJ, Kim JM
- KMID: 2534340
- Clin Mol Hepatol.
- 2022 Oct;28(4):739-753.
- doi: 10.3350/cmh.2022.0060
Liver transplantation (LT) is one of the most effective treatments for hepatocellular carcinoma (HCC). Although LT eliminates HCC and greatly reduces recurrence, some patients experience recurrence after LT. Criteria and... -
- CITED
-
- Close
- SHARE
-
- Close
- The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
-
Lee Y, Kim JH
- KMID: 2534338
- Clin Mol Hepatol.
- 2022 Oct;28(4):706-724.
- doi: 10.3350/cmh.2021.0390
Extracellular vesicles (EVs) are membrane-enclosed particles released from almost all cell types. EVs mediate intercellular communication by delivering their surface and luminal cargoes, including nucleic acids, proteins, and lipids, which... -
- CITED
-
- Close
- SHARE
-
- Close
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
-
Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, Yuen MF
- KMID: 2534353
- Clin Mol Hepatol.
- 2022 Oct;28(4):890-911.
- doi: 10.3350/cmh.2022.0087
Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology,... -
- CITED
-
- Close
- SHARE
-
- Close
- Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis
-
Tan DJH, Quek SXZ, Yong JN, Suresh A, Koh KXM, Lim WH, Quek J, Tang A, Tan C, Nah B, Tan E, Keitoku T, Muthiah MD, Syn N, Ng CH, Kim BK, Tamaki N, Ho CSH, Loomba R, Huang DQ
- KMID: 2534351
- Clin Mol Hepatol.
- 2022 Oct;28(4):864-875.
- doi: 10.3350/cmh.2022.0136
Background/Aims: Depression and anxiety are associated with poorer outcomes in patients with hepatocellular carcinoma (HCC). However, the prevalence of depression and anxiety in HCC are unclear. We aimed to establish... -
- CITED
-
- Close
- SHARE
-
- Close
- Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
-
Kim TH, Jung YK, Yim HJ, Baik JW, Yim SY, Lee YS, Seo YS, Kim JH, Yeon JE, Byun KS
- KMID: 2534352
- Clin Mol Hepatol.
- 2022 Oct;28(4):876-889.
- doi: 10.3350/cmh.2022.0231
Background/Aims: Sarcopenia negatively affects the prognosis of cirrhotic patients, but clinical implications of changes in muscle mass remain unclear. We aimed to elucidate its role in the prognosis of outpatients... -
- CITED
-
- Close
- SHARE
-
- Close
